Actinium Pharmaceuticals (ATNM)

Actinium Pharmaceuticals (ATNM) Income Statement


Actinium Pharmaceuticals Income Statement

Last quarter (Q ), Actinium Pharmaceuticals's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q, Actinium Pharmaceuticals's net income was $-13.28M. See Actinium Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-$ 1.03M$ 1.14M$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
-$ 1.03M$ 1.14M---
Operating Expense
$ 77.39M$ 35.13M$ 26.11M$ 22.39M$ 22.07M$ 23.83M
Operating Income
$ -29.70M$ -34.10M$ -24.96M$ -22.39M$ -22.07M$ -23.83M
Net Non Operating Interest Income Expense
$ 1.54M$ 2.00K$ 190.00K$ 178.00K$ 172.00K$ 173.36K
Other Income Expense
Pretax Income
$ -26.97M$ -33.02M$ -24.77M$ -22.21M$ -21.90M$ -23.65M
Tax Provision
$ -13.80M$ -13.80M$ 373.00K---
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -26.97M$ -33.02M$ -24.77M$ -22.22M$ -21.90M$ -23.65M
Basic EPS
$ -1.93$ -1.37$ -1.20$ -1.83$ -4.50$ -6.60
Diluted EPS
$ -2.16$ -1.37$ -1.20$ -1.83$ -4.50$ -6.60
Basic Average Shares
$ 103.11M$ 24.14M$ 20.57M$ 12.13M$ 4.98M$ 3.53M
Diluted Average Shares
$ 103.11M$ 24.14M$ 20.57M$ 12.13M$ 4.98M$ 3.53M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 77.39M$ 35.13M$ 26.11M$ 22.39M$ 22.07M$ 23.83M
Net Income From Continuing And Discontinued Operation
$ -50.14M$ -33.02M$ -24.77M$ -22.21M$ -21.90M$ -23.65M
Normalized Income
$ -22.48M--$ -22.21M$ -21.90M$ -23.65M
Interest Expense
$ -29.15M$ -33.02M$ -24.96M$ -22.39M$ -22.07M$ -23.83M
$ -28.40M$ -32.32M$ -24.44M$ -21.95M$ -21.65M$ -23.78M
Currency in USD

Actinium Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis